Brief Report: Multi-Institution Real-World Analysis Evaluating Safety, Efficacy, and ctDNA Dynamics After Tarlatamab in Patients With Previously Treated SCLC and LCNEC

Tarlatamab, a bispecific T-cell engager targeting delta-like ligand 3 and CD3 on T cells, has generated impressive treatment response rates in relapsed extensive-stage SCLC and large cell neuroendocrine carcinoma. We performed a retrospective, multi-institutional analysis of 48 patients who received...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Graeme Fenton, MD, Annie L. Zhang, MD, Sharon Zhong, PharmD, Curtis Tatsuoka, PhD, Michelle Sittig, RN, OCN, Alexandra Simms, PharmD, BCOP, Ranee Mehra, MD, Afshin Dowlati, MD, Taofeek K. Owonikoko, MD, PhD, Katherine Scilla, MD, Melinda Hsu, MD, Samuel Rosner, MD
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2026-04-01
coleção:	JTO Clinical and Research Reports
Assuntos:	Small cell lung cancer Tarlatamab Bispecific antibody Real-world Survival analysis ctDNA
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S2666364325001511
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!